Mechanisms of Paclitaxel-induced peripheral neuropathy | ||||
| Journal of advanced Biomedical and Pharmaceutical Sciences | ||||
| Article 4, Volume 6, Issue 1, January 2023, Page 25-35 PDF (475.87 K) | ||||
| Document Type: Review Articles | ||||
| DOI: 10.21608/jabps.2022.170238.1172 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Asmaa Hammad  1; Sayed Ahmed Mohamed M2; Mohamed Khalifa3; Mahmoud El-Daly 4
| ||||
| 1Department of pharmacology and toxicology, faculty of pharmacy, Minia university, Egypt | ||||
| 2Pharmacology and Experimental Oncology Unit, National Cancer Institute, Cairo University, Egypt. | ||||
| 3Department of Pharmacology and Toxicology, Faculty of Pharmacy, Minia University, Egypt | ||||
| 4Department of Pharmacology & Toxicology, Faculty of Pharmacy, Minia University, El-Minia 61519, Egypt | ||||
| Abstract | ||||
| Peripheral neuropathy is a common adverse effect associated with the use of a group of chemotherapeutic agents including paclitaxel (PTX) which negatively affect the quality of life of cancer survivors. In addition, it is considered as a dose-limiting side effect that hinder completion of appropriate chemotherapy regimen. In spite of 27 years of research in mechanisms of PTX neuropathy, there is no approved therapy for prevention of PTX-induced peripheral neuropathy (PIPN). Thus, there is a continuous need to characterize the possible mechanisms associates with PIPN in order to find appropriate targeted therapy for this clinical problem. In this review, we summarized most of the recent findings of the cellular targets implicated in PIPN. | ||||
| Keywords | ||||
| Paclitaxel neuropathy; immune reaction; axonal transport; mitochondrial dysfunction | ||||
|
Statistics Article View: 373 PDF Download: 659 |
||||
